Bei B. Zhang
Pfizer (United States)(US)
Publications by Year
Research Areas
Pancreatic function and diabetes, Metabolism, Diabetes, and Cancer, Diabetes Treatment and Management, Adipose Tissue and Metabolism, Receptor Mechanisms and Signaling
Most-Cited Works
- → AMPK: An Emerging Drug Target for Diabetes and the Metabolic Syndrome(2009)1,029 cited
- → Metabolic Dysregulation and Adipose Tissue Fibrosis: Role of Collagen VI(2008)1,018 cited
- → Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin(2010)872 cited
- → Glucagon and regulation of glucose metabolism(2003)868 cited
- → Hypothalamic insulin signaling is required for inhibition of glucose production(2002)857 cited
- → (2R)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes(2004)814 cited
- → The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL(2017)634 cited
- → Induction of Adipocyte Complement-Related Protein of 30 Kilodaltons by PPARγ Agonists: A Potential Mechanism of Insulin Sensitization(2002)567 cited
- → GDF15 Provides an Endocrine Signal of Nutritional Stress in Mice and Humans(2019)480 cited
- → Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic β-Cell Mass and Function in a Rodent Model of Type 2 Diabetes(2006)450 cited